Roundview Capital LLC increased its stake in shares of Novartis AG (NYSE:NVS) by 14.1% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 8,255 shares of the company’s stock after acquiring an additional 1,020 shares during the period. Roundview Capital LLC’s holdings in Novartis were worth $693,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of NVS. Buckley Wealth Management LLC acquired a new stake in Novartis during the 4th quarter valued at $363,000. Gratus Capital LLC increased its holdings in Novartis by 12.3% during the 4th quarter. Gratus Capital LLC now owns 111,836 shares of the company’s stock valued at $9,390,000 after purchasing an additional 12,267 shares in the last quarter. Carmichael Hill & Associates Inc. acquired a new stake in Novartis during the 4th quarter valued at $410,000. Tradition Capital Management LLC increased its holdings in Novartis by 0.9% during the 4th quarter. Tradition Capital Management LLC now owns 69,381 shares of the company’s stock valued at $5,825,000 after purchasing an additional 652 shares in the last quarter. Finally, Rench Wealth Management Inc. increased its holdings in Novartis by 6.8% during the 4th quarter. Rench Wealth Management Inc. now owns 31,563 shares of the company’s stock valued at $2,650,000 after purchasing an additional 2,003 shares in the last quarter. Institutional investors and hedge funds own 11.06% of the company’s stock.

NVS has been the subject of a number of recent analyst reports. Leerink Swann raised their price target on Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a report on Monday, October 23rd. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Novartis in a report on Tuesday, October 24th. Barclays cut Novartis from an “equal weight” rating to an “underweight” rating in a report on Wednesday, October 25th. Zacks Investment Research raised Novartis from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. Finally, Bank of America cut Novartis from a “neutral” rating to an “underperform” rating in a report on Wednesday, December 6th. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $85.32.

Shares of Novartis AG (NYSE:NVS) opened at $83.25 on Monday. The company has a market capitalization of $192,928.22, a price-to-earnings ratio of 25.62, a PEG ratio of 1.94 and a beta of 0.73. Novartis AG has a 52 week low of $72.67 and a 52 week high of $94.19. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91.

Novartis (NYSE:NVS) last released its earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.16 by $0.04. The company had revenue of $12.92 billion during the quarter, compared to analysts’ expectations of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. The business’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same period last year, the firm earned $1.14 EPS. sell-side analysts predict that Novartis AG will post 5.36 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Roundview Capital LLC Has $693,000 Position in Novartis AG (NVS)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.watchlistnews.com/roundview-capital-llc-has-693000-position-in-novartis-ag-nvs/1861463.html.

About Novartis

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.